T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to study the impact of ipilimumab on the immune
system of patients currently receiving hormone therapy. The safety of these drug combinations
will also be studied.
This is an investigational study. Ipilimumab is FDA approved and commercially available for
the treatment of melanoma. Its use to treat prostate cancer is investigational.
Up to 30 patients will take part in this study. All will be enrolled at MD Anderson.
Phase:
Early Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Bristol-Myers Squibb High Impact Clinical Research Support Program Stand Up To Cancer